Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor

Summary by MarketBeat
Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.

1 Articles

MarketBeatMarketBeat
Center

Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor

Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Wednesday, October 14, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Diabetes icon

Diabetes

San Diego icon

San Diego

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal